Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy

• Published in: Journal of biomedical materials research. Part A Vol. 108; no. 3; pp. 565 - 580
• Main Authors: Remant, KC, Thapa, Bindu, Valencia‐Serna, Juliana, Domun, Suraj S., Dimitroff, Cailean, Jiang, Xiaoyan, Uludağ, Hasan
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-03-2020; Wiley Subscription Services, Inc
• Subjects: Apoptosis; BCR protein; Caspase; Cations; Cholesterol; cholesterol‐grafting; Chronic myeloid leukemia; Fluorescence; Gene silencing; Grafting; Green fluorescent protein; growth arrest; Hydrophobicity; Leukemia; lipopolymers; Molecular weight; Myeloid leukemia; Polyethyleneimine; siRNA; siRNA delivery; Therapy; growth arrest; siRNA delivery; chronic myeloid leukemia; lipopolymers; cholesterol-grafting
• ISSN: 1549-3296; 1552-4965
• DOI: 10.1002/jbm.a.36837

Synthetic siRNA technology has emerged as a promising approach for molecular therapy of cancer but, despite its potential for post‐transcriptional gene silencing, there is an urgent need to develop efficient delivery systems particularly for difficult‐to‐transfect, anchorage‐independent cells. In this study, we designed highly hydrophobic cationic lipopolymers by grafting cholesterol (Chol) onto low‐molecular weight (0.6, 1.2, and 2.0 kDa) polyethylenimines (PEIs) to enable specific siRNA therapy to chronic myeloid leukemia (CML) cells. The siRNA binding by PEI‐Chol led to nano‐sized (100–200 nm diameter) polyplexes with enhanced ζ‐potential (+20 to +35 mV) and ability to protect the loaded siRNA completely in fresh serum. The siRNA delivery to CML (K562) cells was proportional to degree of substitution and, unexpectedly, inversely proportional to molecular size of the polymeric backbone. Chol grafting with as little as ~1.0 Chol/PEI on 0.6 and 1.2 kDa PEIs enabled silencing of the reporter Green Fluorescent Protein gene as well as the endogenous BCR‐Abl oncogene in K562 cells. The PEI‐Chol mediated delivery of siRNAs specific for BCR‐Abl and KSP genes significantly arrested the growth the cells which was significantly reflected in colony formation potency of K562 cells. BCR‐Able siRNA mediated therapeutic efficacy was also observed in significantly increased caspase activity and apoptosis of K562 cells. Thus, Chol‐grafted low‐molecular weight PEIs appear to be unique siRNA carriers to realize the molecular therapy in CML cells.